Adefovir

Type: Keyphrase

Name: Adefovir

First Reported 10/31/2009 - Updated 10/31/2009 - 3 Documents (in Health)

Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating Viread(R) For...

BusinessWire - Gilead Sciences, Inc. (Nasdaq:GILD) today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread(R) (tenofovir ... [Forbes.com - 10/31/2009]

Entities: Tenofovir, Adefovir, HIV/AIDS, creatinine

First Reported 10/31/2009 - Updated 10/31/2009 - 1 Documents (in Medicine)

Bristol-Myers Squibb Company

Bristol-Myers Says BARACLUDE Demonstrated Greater Antiviral Efficacy Compared To Adefovir In New Study Of Chronic Hepatitis B - Quick Facts

(RTTNews) - Bristol-Myers Squibb (BMY: News ) revealed 48-week data from an ongoing study, or ETV-048, of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new ... [RTTNews.com - 10/31/2009]

Entities: Adefovir, Bristol-Myers Squibb Company, Hepatitis B

First Reported 11/03/2009 - Updated 11/03/2009 - 1 Documents

Patients Previously Treated With Adefovir Can Achieve Complete Viral Suppression When Switched to Entecavir: Presented at AASLD

-- Patients with hepatitis B virus (HBV) previously treated with adefovir (ADV) had complete viral suppression (CVS) and alanine aminotransferase (ALT) normalisation when switched to entecavir (ETV), researchers stated here at the Liver Meeting 2009, ... [PSL Group - 11/03/2009]

Entities: Entecavir, Adefovir, Suppression

First Reported 11/03/2009 - Updated 11/03/2009 - 1 Documents (in Biology)

Bristol-Myers Squibb on Baraclude: Better efficacy than competitor

BOSTON (Nov. 3) A Bristol-Myers Squibb drug used to treat hepatitis B kept viral load levels down more effectively than its competitor, according to study results announced by the company.Bristol presented results in Boston Saturday at the American Association ... [Drug Store News - 11/03/2009]

Entities: Bristol-Myers Squibb Company, Adefovir, efficacy, Cirrhosis

First Reported 11/06/2009 - Updated 11/06/2009 - 1 Documents (in Medicine)

Entecavir (Baraclude) Demonstrates Greater Antiviral Activity than Adefovir (Hepsera) in Hepatitis B Patients with Decompensated Liver Disease

To explore this issue, an international team of investigators conducted a randomized, open-label, Phase 3b study (ETV-048) comparing 1.0 mg/day entecavir versus 10 mg/day adefovir in this population. A total of 100 participants randomly assigned to the ... [HIV and Hepatitis.com - 11/06/2009]

Entities: Adefovir, Entecavir, Hepatitis B, Antiviral

First Reported 11/12/2009 - Updated 11/12/2009 - 1 Documents (in Health)

Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating VireadÂ® for Chronic Hepatitis B

Gilead Sciences, Inc. (Nasdaq:GILD) announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread (tenofovir disoproxil fumarate) ... [Pharmacy Choice - 11/12/2009]

Entities: Tenofovir, Adefovir, HIV/AIDS, creatinine

First Reported 06/23/2009 - Updated 06/23/2009 - 1 Documents

ORIGINAL ARTICLE: Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

Background: Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase.Methods: In two double-blind,... ... [NEJM â Collection Updates for Viral Diseases - 06/23/2009]

Entities: Tenofovir, Adefovir, Hepatitis B

Quotes

...patient population,' said ETV-048 study investigator Hugo Cheinquer in a press release issued by entecavir manufacturer Bristol-Myers Squibb. "Chronic hepatitis B is a lifelong disease and these data suggest that treatment with Baraclude may offer patients with decompensated cirrhosis a treatment option." Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan; Aristotle University of Thessaloniki, Thessaloniki, Greece;...

Entecavir (Baraclude) Demonstrates Greater Antiviral Activity than Adefovir (Hepsera) in Hepatiti ... [HIV and Hepatitis.com - 11/06/2009]

More Content

sort by: Date \| Relevance
Drug Price/Cost Debate Report: Swine Flu Vaccin... [Pharmacy Choice - 11/18/2009]
Research and Markets: Drug Price/Cost Debate: G... [Yahoo! Canada - 11/17/2009]
Research and Markets: Drug Price/Cost Debate: G... [Forbes.com - 11/17/2009]
Gilead Announces Long-Term Data from Two Pivota... [Pharmacy Choice - 11/12/2009]
Trends in Waiting List Registration for Liver T... [National AIDS Treatment Advocacy Project - 11/07/2009]
Entecavir (Baraclude) Demonstrates Greater Anti... [HIV and Hepatitis.com - 11/06/2009]
Bristol-Myers Squibb on Baraclude: Better effic... [Drug Store News - 11/03/2009]
Patients Previously Treated With Adefovir Can A... [PSL Group - 11/03/2009]
Bristol-Myers Says BARACLUDE Demonstrated Great... [RTTNews.com - 10/31/2009]
BARACLUDE(R) (entecavir) Demonstrated Greater A... [Forbes.com - 10/31/2009]
Gilead Announces Long-Term Data from Two Pivota... [Forbes.com - 10/31/2009]
Gilead Announces Long-Term Data from Two Pivota... [Business Wire via MSN Money - 10/31/2009]
Gilead Announces Long-Term Data from Two Pivota... [Street Insider - 10/31/2009]
Gilead Sciences gibt Rekord-Finanzergebnis f... [FinanzNachrichten.de - 10/24/2009]
Gilead Sciences, Inc. Q3 2009 Earnings Call Tra... [Seeking Alpha - 10/21/2009]
Hepatitis B Virus Genotypes E, F, G, and H Appe... [HIV and Hepatitis.com - 10/18/2009]

Log in to Silobreaker

Advanced Search Options

Adefovir